Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELUW) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Celularity (CELUW) over the last 6 years, with Q3 2025 value amounting to -$98000.0.

  • Celularity's Asset Writedowns and Impairment fell 1666.67% to -$98000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $84000.0, marking a year-over-year decrease of 6216.22%. This contributed to the annual value of $457000.0 for FY2024, which is 9957.61% down from last year.
  • Latest data reveals that Celularity reported Asset Writedowns and Impairment of -$98000.0 as of Q3 2025, which was down 1666.67% from $8000.0 recorded in Q2 2025.
  • In the past 5 years, Celularity's Asset Writedowns and Impairment registered a high of $107.2 million during Q2 2023, and its lowest value of -$232000.0 during Q2 2022.
  • For the 5-year period, Celularity's Asset Writedowns and Impairment averaged around $6.5 million, with its median value being $174000.0 (2021).
  • The largest annual percentage gain for Celularity's Asset Writedowns and Impairment in the last 5 years was 4900000.0% (2022), contrasted with its biggest fall of 23333.33% (2022).
  • Quarter analysis of 5 years shows Celularity's Asset Writedowns and Impairment stood at $185000.0 in 2021, then skyrocketed by 384.32% to $896000.0 in 2022, then surged by 11863.06% to $107.2 million in 2023, then plummeted by 99.78% to $235000.0 in 2024, then crashed by 141.7% to -$98000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$98000.0 for Q3 2025, versus $8000.0 for Q2 2025 and -$61000.0 for Q1 2025.